రొమ్ము క్యాన్సర్: ప్రస్తుత పరిశోధన

నైరూప్య

Preclinical Evidence versus Clinical Outcomes in CAR and Fc-CR T Cell Immunotherapy for Breast Cancer

Asma Arriga

Immunotherapy, specifically Chimeric Antigen Receptor (CAR) T cell and Fc-receptor-enhanced chimeric receptor (Fc-CR) T cell therapies, has emerged as a promising approach for treating cancer. The development and translation of these therapies from preclinical studies to clinical applications represent a critical phase in their evaluation. This abstract highlights the essential aspects of the relationship between preclinical evidence and clinical outcomes in CAR and Fc-CR T cell immunotherapy for cancer. In preclinical research, CAR and Fc-CR T cells have demonstrated impressive anti-tumor efficacy, targeting a wide range of tumor antigens. However, the translation of these findings into clinical practice has brought to light a series of challenges. Factors such as tumor microenvironment, patient heterogeneity, and safety concerns have influenced the clinical performance of these therapies, often leading to outcomes that differ from preclinical expectations. This abstract explores the critical components of preclinical evidence, including in vitro and animal model studies, and their implications on clinical outcomes. It examines the discordance between preclinical promise and clinical reality, shedding light on the factors that contribute to this discrepancy. Furthermore, we discuss the strategies and ongoing efforts to bridge the gap between preclinical and clinical results, emphasizing the need for improved predictive models and patient stratification. Understanding the complex relationship between preclinical evidence and clinical outcomes in CAR and Fc-CR T cell immunotherapy is essential for advancing the field and enhancing the effectiveness of these groundbreaking cancer treatments. By addressing the challenges and optimizing the translational process, researchers and clinicians can improve the prospects of delivering innovative, personalized, and more efficacious cancer immunotherapies to patients in the future